A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

DOI: 10.1634/theoncologist.2016-0038

Keywords: MET, Gastric cancer, Chemotherapy, Onartuzumab, HER2-negative, First line

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text